Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Role of Cxc Chemokines and Receptors in Breast Cancer Publisher Pubmed

Summary: CXC chemokines gone rogue in breast cancer? Review shows dysregulation aids metastasis, angiogenesis. Research suggests CXCRs as biomarkers/targets—personalized therapies ahead? #BreastCancer #Chemokines

Masrour M1, 2 ; Moeinafshar A1 ; Poopak A1 ; Razi S3, 4 ; Rezaei N4, 5, 6
Authors

Source: Clinical and Experimental Medicine Published:2025


Abstract

CXC chemokines are a class of cytokines possessing chemotactic properties. Studies indicate that CXC chemokines exhibit dysregulation in miscellaneous cancer categories and are significantly associated with the advancement of tumors. Breast cancer is a commonly diagnosed and fatal cancer among the female population. Breast cancer pathogenesis and progression involve various mechanisms, including invasion, metastasis, angiogenesis, and inflammation. Chemokines and their receptors are involved in all of these processes. The CXC chemokine receptors (CXCRs) and their related ligands have attracted considerable attention due to their multifaceted functions in facilitating and controlling tumor proliferation. CXCRs are expressed by both cancer cells and immune cells, and they play a crucial role in regulating the tumor microenvironment and the immune response. This review aims to assess the potential of CXCRs and CXC chemokines as therapeutic targets or biomarkers for personalized therapy. Additionally, it provides an overview of the current understanding of the expression, function, and prognostic relevance of CXCRs in breast cancer. Furthermore, the challenges and potential prospects pertaining to CXCR investigation in breast cancer are deliberated. © The Author(s) 2025.
Other Related Docs
11. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
15. Breast Tumor Targeting in Mice Bearing 4T1 Tumor With Labeled Cxcr4 Antagonist Analogue, International Journal of Peptide Research and Therapeutics (2021)
18. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)